AFMD News and Press, Affimed N.V. From 09/04/22

Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not reached Stable disease was observed in 10 of 27 evaluable patients in an unselected patient population Comprehensive pharmacodynamic studies ind...

U.S. stock markets have been exceedingly volatile in 2022. This turbulent environment hasn't kept some of the world's best investors on the sidelines, however. The billionaire brothers Julian and Felix Baker -- co-owners of the biotechnology focused hedge fund Baker Bros. Advisors -- ar...

Affimed NV (AFMD) Q2 2022 Earnings Conference Call August 11, 2022, 08:30 ET Company Participants Alexander Fudukidis - Head, IR Adi Hoess - CEO Angus Smith - CFO Andreas Harstrick - Chief Medical Officer Conference Call Participants Daina Graybos...

With its Q2 financials for 2022, German biotech Affimed N.V. ( NASDAQ: AFMD ) announced on Thursday that following the feedback from the FDA, the company decided to voluntarily withdraw the investigational new drug (IND) application for myeloid leukemia candidate AFM28 in the ...

Affimed press release ( NASDAQ: AFMD ): Q2 GAAP EPS of -€0.13. Revenue of €7.3M (-24.8% Y/Y). As of June 30, 2022 cash and cash equivalents totaled €237.2 million compared to €197.6 million on December 31, 2021. Based on the Company&#x...

AFM13 monotherapy: On track to report topline data of the registration-directed REDIRECT trial in the fourth quarter of 2022 AFM13 combination with natural killer (NK) cells: On track to report updated data at a scientific conference in the fourth quarter of 2022 AFM24: Studies co...

Affimed ( NASDAQ: AFMD ) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.18 (-12.5% Y/Y) and the consensus Revenue Estimate is $8.03M (-17.3% Y/Y). Over the last 3 months, EPS estimates have s...

HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article covers six blue-chip stocks to sell now. These stocks are severely overvalued or are likely to move down soon due to the coming recession or a slump in demand. The point is analysts’ forecasts are like...

Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and oncology Scientific Advisory Board to provide guidance on the Company’s development strategy across assets and assessment of emerg...